Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
Search
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
Our People, Our Culture
Our People, Our Culture
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Skin and Inflammatory Diseases
skin diseases
Fremont, CA site
Fremont, CA site
Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Brigitte Fuhr
Our data transformation
The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US
The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions
Looking Ahead at Recruitment in the Biopharma Industry
Looking Ahead at Recruitment in the Biopharma Industry
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Nick Gollop
Nick Gollop loves making a difference for patients and their families as a Senior Global Clinical Programme Leader in Clinical Development.
Generalized Pustular Psoriasis: Impact Beyond the Skin
Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
Scleroderma
Scleroderma
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Prescription Digital Therapeutics a New Frontier in Mental Health Care
Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.
Respiratory
Respiratory